<SEC-DOCUMENT>0001104659-25-101914.txt : 20251024
<SEC-HEADER>0001104659-25-101914.hdr.sgml : 20251024
<ACCEPTANCE-DATETIME>20251023202751
ACCESSION NUMBER:		0001104659-25-101914
CONFORMED SUBMISSION TYPE:	D
PUBLIC DOCUMENT COUNT:		1
ITEM INFORMATION:		Rule 506(b) provides a "safer harbor" for a private offering
FILED AS OF DATE:		20251024
DATE AS OF CHANGE:		20251023
EFFECTIVENESS DATE:		20251024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		D
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	021-561937
		FILM NUMBER:		251414081

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<edgarSubmission>

    <schemaVersion>X0708</schemaVersion>

    <submissionType>D</submissionType>

    <testOrLive>LIVE</testOrLive>

    <primaryIssuer>
        <cik>0000894158</cik>
        <entityName>Theriva Biologics, Inc.</entityName>
        <issuerAddress>
            <street1>9605 MEDICAL CENTER DRIVE</street1>
            <street2>SUITE 270</street2>
            <city>ROCKVILLE</city>
            <stateOrCountry>MD</stateOrCountry>
            <stateOrCountryDescription>MARYLAND</stateOrCountryDescription>
            <zipCode>20850</zipCode>
        </issuerAddress>
        <issuerPhoneNumber>301-417-4364</issuerPhoneNumber>
        <jurisdictionOfInc>NEVADA</jurisdictionOfInc>
        <issuerPreviousNameList>
            <previousName>SYNTHETIC BIOLOGICS, INC.</previousName>
        </issuerPreviousNameList>
        <edgarPreviousNameList>
            <previousName>Synthetic Biologics, Inc.</previousName>
            <previousName>ADEONA PHARMACEUTICALS, INC.</previousName>
            <previousName>PIPEX PHARMACEUTICALS, INC.</previousName>
        </edgarPreviousNameList>
        <entityType>Corporation</entityType>
        <yearOfInc>
            <overFiveYears>true</overFiveYears>
        </yearOfInc>
    </primaryIssuer>

    <relatedPersonsList>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Steven</firstName>
                <middleName>A.</middleName>
                <lastName>Shallcross</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>9605 Medical Center Drive</street1>
                <street2>Suite 270</street2>
                <city>Rockville</city>
                <stateOrCountry>MD</stateOrCountry>
                <stateOrCountryDescription>MARYLAND</stateOrCountryDescription>
                <zipCode>20850</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Executive Officer</relationship>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Jeffrey</firstName>
                <middleName>J.</middleName>
                <lastName>Kraws</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>9605 Medical Center Drive</street1>
                <street2>Suite 270</street2>
                <city>Rockville</city>
                <stateOrCountry>MD</stateOrCountry>
                <stateOrCountryDescription>MARYLAND</stateOrCountryDescription>
                <zipCode>20850</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>John</firstName>
                <lastName>Monahan</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>9605 Medical Center Drive</street1>
                <street2>Suite 270</street2>
                <city>Rockville</city>
                <stateOrCountry>MD</stateOrCountry>
                <stateOrCountryDescription>MARYLAND</stateOrCountryDescription>
                <zipCode>20850</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
        <relatedPersonInfo>
            <relatedPersonName>
                <firstName>Jeffrey</firstName>
                <middleName>A.</middleName>
                <lastName>Wolf</lastName>
            </relatedPersonName>
            <relatedPersonAddress>
                <street1>9605 Medical Center Drive</street1>
                <street2>Suite 270</street2>
                <city>Rockville</city>
                <stateOrCountry>MD</stateOrCountry>
                <stateOrCountryDescription>MARYLAND</stateOrCountryDescription>
                <zipCode>20850</zipCode>
            </relatedPersonAddress>
            <relatedPersonRelationshipList>
                <relationship>Director</relationship>
            </relatedPersonRelationshipList>
        </relatedPersonInfo>
    </relatedPersonsList>

    <offeringData>
        <industryGroup>
            <industryGroupType>Biotechnology</industryGroupType>
        </industryGroup>
        <issuerSize>
            <revenueRange>Decline to Disclose</revenueRange>
        </issuerSize>
        <federalExemptionsExclusions>
            <item>06b</item>
        </federalExemptionsExclusions>
        <typeOfFiling>
            <newOrAmendment>
                <isAmendment>false</isAmendment>
            </newOrAmendment>
            <dateOfFirstSale>
                <value>2025-10-17</value>
            </dateOfFirstSale>
        </typeOfFiling>
        <durationOfOffering>
            <moreThanOneYear>false</moreThanOneYear>
        </durationOfOffering>
        <typesOfSecuritiesOffered>
            <isOptionToAcquireType>true</isOptionToAcquireType>
            <isSecurityToBeAcquiredType>true</isSecurityToBeAcquiredType>
        </typesOfSecuritiesOffered>
        <businessCombinationTransaction>
            <isBusinessCombinationTransaction>false</isBusinessCombinationTransaction>
        </businessCombinationTransaction>
        <minimumInvestmentAccepted>0</minimumInvestmentAccepted>
        <salesCompensationList>
            <recipient>
                <recipientName>A.G.P./Alliance Global Partners</recipientName>
                <recipientCRDNumber>000008361</recipientCRDNumber>
                <associatedBDName>None</associatedBDName>
                <associatedBDCRDNumber>None</associatedBDCRDNumber>
                <recipientAddress>
                    <street1>590 MADISON AVENUE</street1>
                    <street2>36th Floor</street2>
                    <city>New York</city>
                    <stateOrCountry>NY</stateOrCountry>
                    <stateOrCountryDescription>NEW YORK</stateOrCountryDescription>
                    <zipCode>10022</zipCode>
                </recipientAddress>
                <statesOfSolicitationList>
                    <state>CA</state>
                    <description>CALIFORNIA</description>
                    <state>IL</state>
                    <description>ILLINOIS</description>
                    <state>NY</state>
                    <description>NEW YORK</description>
                </statesOfSolicitationList>
                <foreignSolicitation>true</foreignSolicitation>
            </recipient>
        </salesCompensationList>
        <offeringSalesAmounts>
            <totalOfferingAmount>13109494</totalOfferingAmount>
            <totalAmountSold>13109494</totalAmountSold>
            <totalRemaining>0</totalRemaining>
            <clarificationOfResponse>Includes $4,369,831.20 in proceeds from exercise of existing registered warrants pursuant to Warrant Inducement  Letter Agreement and $8,739,663 in total gross proceeds to be received from cash exercise of all new warrants  issued in private placement.</clarificationOfResponse>
        </offeringSalesAmounts>
        <investors>
            <hasNonAccreditedInvestors>false</hasNonAccreditedInvestors>
            <totalNumberAlreadyInvested>10</totalNumberAlreadyInvested>
        </investors>
        <salesCommissionsFindersFees>
            <salesCommissions>
                <dollarAmount>308000</dollarAmount>
                <isEstimate>true</isEstimate>
            </salesCommissions>
            <findersFees>
                <dollarAmount>0</dollarAmount>
            </findersFees>
            <clarificationOfResponse>A.G.P/Alliance Global Partners LP was paid by the Issuer a cash fee equal to 7.0% of the aggregate gross proceeds received  upon exercise of the existing registered warrants and reimbursement of certain expenses.</clarificationOfResponse>
        </salesCommissionsFindersFees>
        <useOfProceeds>
            <grossProceedsUsed>
                <dollarAmount>0</dollarAmount>
            </grossProceedsUsed>
            <clarificationOfResponse>While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some  proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive  officers</clarificationOfResponse>
        </useOfProceeds>
        <signatureBlock>
            <authorizedRepresentative>false</authorizedRepresentative>
            <signature>
                <issuerName>Theriva Biologics, Inc.</issuerName>
                <signatureName>/s/ Steven A. Shallcross</signatureName>
                <nameOfSigner>Steven A. Shallcross</nameOfSigner>
                <signatureTitle>Chief Executive Officer and Chief Financial Officer</signatureTitle>
                <signatureDate>2025-10-23</signatureDate>
            </signature>
        </signatureBlock>
    </offeringData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
